Armata Pharmaceuticals (ARMP) Net Cash Flow (2013 - 2026)

Armata Pharmaceuticals has disclosed Net Cash Flow across 14 years of filings, most recently posting -$5.2 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$5.2 million, down 325.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 68.76% YoY), and the FY2025 annual result was -$693000.0, up 84.5% from the prior year.
• Net Cash Flow came in at -$5.2 million for Q1 2026 at Armata Pharmaceuticals, up from -$6.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $40.9 million in Q1 2022 to a low of -$12.6 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$7.4 million (2025), against an average of -$153764.7.
• Peak annual rise in Net Cash Flow reached 219.23% in 2022, while the deepest fall reached 488.93% in 2022.
• Armata Pharmaceuticals' Net Cash Flow stood at -$10.5 million in 2022, then declined by 0.09% to -$10.5 million in 2023, then climbed by 25.51% to -$7.8 million in 2024, then rose by 22.7% to -$6.1 million in 2025, then advanced by 14.24% to -$5.2 million in 2026.
• The last three Net Cash Flow figures came in at -$5.2 million (Q1 2026), -$6.1 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.